Las Vegas – – September 11, 2026 -- The sarcoidosis treatment market across the seven major markets is projected to expand steadily through 2036, driven by a pipeline of seven late- and mid-stage drug candidates targeting a disease that affects an estimated 150,000 to 200,000 patients annually in the United States alone, according to a new market report from DelveInsight.
Shanghai – September 11, 2026 -- Natural Field has expanded its NF TriSolve® nutraceutical solution platform into the sleep wellness category, launching NF TriSolve® SleepRestore Complex after preclinical testing showed a 39% improvement in sleep performance versus a model control group.
The Shanghai-based nutraceutical ingredient solutions provider built the new formulation by integrating multiple functional components into a single coordinated concept aimed at global nutrition and supplement brands developing differentiated sleep products. The launch follows Natural Field's earlier work on healthy aging and joint wellness solutions under the same branded platform.
Shanghai – September 11, 2026 -- Natural Field has extended its NF TriSolve® nutraceutical solutions platform into the sleep wellness category with the launch of the NF TriSolve® SleepRestore complex.
The SleepRestore complex integrates several functional components within a single formulation concept designed for nutraceutical applications targeting sleep. The launch marks Natural Field's entry into the expanding sleep wellness market, built on a solutions-oriented development approach rather than single-ingredient focus.
Delray Beach – – September 11, 2026 -- The global carboxymethylcellulose calcium market will grow from $0.06 billion in 2026 to $0.09 billion by 2036, expanding at a compound annual growth rate of 4.8%, according to a new MarketsandMarkets forecast.
Asia Pacific is projected to post the highest CAGR of 5.2% over the forecast period, driven by expanding pharmaceutical manufacturing in China and India, rising generic drug output, and growing contract manufacturing activity. Well-established supply chains in both countries are reinforcing cost-efficient production and rising domestic consumption of cellulose-based excipients.
Tel Aviv – – September 11, 2026 -- The Israel National Biotech Innovation Center (INBI) officially launched operations, uniting 15 of Israel's top universities, research institutions and healthcare organizations under a single translational platform for the first time.
Anat Cohen-Dayag, PhD, Executive Chairperson of Compugen and formerly its President and CEO for 15 years, has been appointed Chief Executive Officer of INBI Core Ltd., the wholly owned operational subsidiary of INBI. Samuel Moed, former Senior Vice President of Corporate Strategy at Bristol Myers Squibb, will chair both INBI and INBI Core.
Rockville, Maryland – September 11, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will hold fireside chats at two major investor healthcare conferences in New York this month.
The gene therapy company will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15 at 8:30 a.m. ET, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 at 8:30 a.m. ET. Both sessions will take place in New York, NY.
Hong Kong – September 11, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) has initiated a U.S. Phase I trial of ASC36, an oral amylin receptor peptide agonist for obesity, after securing Investigational New Drug clearance from the FDA.
The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ASC36 across single and multiple ascending oral doses in 86 participants with obesity (BMI ≥ 30.0 kg/m2) or overweight status (BMI ≥ 27.0 kg/m2). This marks the fourth Phase I peptide study Ascletis has launched in 2026.
Burlington, N.C. – September 11, 2026 -- Labcorp (NYSE: LH) has acquired MLM Medical Labs, a central and specialty laboratory provider with operations in the United States, Germany and South Africa, financial terms undisclosed.
The deal extends Labcorp's laboratory footprint across North America, Europe, Asia and Africa, combining its global scale with MLM's regional laboratory network and biomarker testing capabilities. The transaction strengthens Labcorp's position as an independent central laboratory services provider for clinical trial sponsors.
Sugar Land, Texas – September 11, 2026 -- QuVa Pharma, Inc. has acquired a portfolio of essential sterile compounded medications from Central Admixture Pharmacy Services, Inc. (CAPS) after CAPS decided to exit the 503B sterile compounding business, the companies announced.
QuVa expects to begin introducing selected products from the acquired portfolio in phases later in 2026, with plans to expand offerings over the following six months. The deal covers critical medication categories including Cardioplegia, Total Parenteral Nutrition and Heparin.
Cambridge, Massachusetts – September 11, 2026 -- Harbour BioMed (HKEX: 02142) and partner Windward Bio reported positive Phase 2 interim results for HBM9378/WIN378, a twice-yearly TSLP-blocking antibody, from the 147-patient POLARIS-1 asthma trial, clearing the path for two Phase 3 studies.
The Phase 2 interim analysis, conducted on the first 98 of 147 enrolled patients with uncontrolled moderate-to-severe asthma, found FEV1 increases of up to 174 mL, with a placebo-adjusted mean increase of 256 mL (p=0.033) at Week 24 after a single dose.
FeNO fell by up to 24 ppb, a 43% reduction (p=0.006), while blood eosinophil counts dropped by up to 200 cells/μL, a 51% decline (p0.0001). Near-maximal effects appeared as early as Week 2 and were sustained through Week 24.